[HTML][HTML] Targeting the cholinergic system to develop a novel therapy for Huntington's disease
GX D'Souza, HJ Waldvogel - Journal of Huntington's Disease, 2016 - content.iospress.com
In this review, we outline the role of the cholinergic system in Huntington's disease, and
briefly describe the dysfunction of cholinergic transmission, cholinergic neurons, cholinergic …
briefly describe the dysfunction of cholinergic transmission, cholinergic neurons, cholinergic …
Emerging drug therapies in Huntington's disease
Huntington's disease (HD) is a relentless neurodegenerative disease that results in
profound disability through a triad of motor, cognitive and neuropsychiatric symptoms. At …
profound disability through a triad of motor, cognitive and neuropsychiatric symptoms. At …
[HTML][HTML] Therapeutic advances in the management of Huntington's disease
GO Abdulrahman Jr - The Yale journal of biology and medicine, 2011 - ncbi.nlm.nih.gov
Trinucleotide repeat disorders are a set of genetic disorders characterized by the expansion
of certain genes of a segment of DNA that contains a repeat of three nucleotides, thus …
of certain genes of a segment of DNA that contains a repeat of three nucleotides, thus …
Recent advances in Huntington's disease: implications for experimental therapeutics
A Feigin, D Zgaljardic - Current opinion in neurology, 2002 - journals.lww.com
Recent advances in the understanding of the molecular biology and pathophysiology of
Huntington's disease have suggested new therapeutic strategies aimed at slowing …
Huntington's disease have suggested new therapeutic strategies aimed at slowing …
Huntington and its role in neuronal degeneration
SH Li, XJ Li - The Neuroscientist, 2004 - journals.sagepub.com
Huntington's disease results from a polyglutamine expansion in the N-terminal region of
huntingtin (htt). This abnormality causes protein aggregation and leads to neurotoxicity …
huntingtin (htt). This abnormality causes protein aggregation and leads to neurotoxicity …
[HTML][HTML] Huntington's disease: From basic science to therapeutics
C Cepeda, XP Tong - CNS neuroscience & therapeutics, 2018 - ncbi.nlm.nih.gov
In 1872, George Huntington, an American physician who at the time was only 22 years old,
published a short communication in the “Medical and Surgical Reporter”(Philadelphia) …
published a short communication in the “Medical and Surgical Reporter”(Philadelphia) …
[HTML][HTML] Huntington's disease: from disease mechanisms to therapies
C Blackstone - Drug discovery today, 2014 - ncbi.nlm.nih.gov
Huntington's disease (HD) is a relentlessly degenerative disorder of the central nervous
system, affecting the striatum most prominently, but also the cerebral cortex and other …
system, affecting the striatum most prominently, but also the cerebral cortex and other …
Huntington's disease: pathomechanism and therapeutic perspectives
G Gárdián, L Vécsei - Journal of Neural Transmission, 2004 - Springer
Huntington's disease is an autosomal dominantly inherited progressive neurodegenerative
disorder. The mutant gene has been localised to chromosome 4p16. 3. The gene product …
disorder. The mutant gene has been localised to chromosome 4p16. 3. The gene product …
Huntington's Disease: Pathogenic mechanisms and therapeutic targets
Huntington's disease (HD) is a tandem repeat disorder involving neurodegeneration and a
complex combination of symptoms. These include psychiatric symptoms, cognitive deficits …
complex combination of symptoms. These include psychiatric symptoms, cognitive deficits …
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments
E Roze, F Saudou, J Caboche - Current opinion in neurology, 2008 - journals.lww.com
Pathophysiology of Huntington's disease: from huntingtin fun... : Current Opinion in Neurology
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments …
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments …